Vertex Pharmaceuticals (VRTX) Net Cash Flow Growth (5y) (2014 - 2026)
Powered by 
Analysis
Vertex Pharmaceuticals (VRTX) Net Cash Flow Growth (5y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.70 Bn | 58.52 Bn | 1.37 Bn |
| 4 | Moderna | 57.56 Bn | 52.42 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 40.16 Bn | 35.06 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.63 Bn | 32.32 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.63 Bn | 27.79 Bn | - |
| 9 | Insmed | 27.73 Bn | 26.57 Bn | 358.27 Mn |
| 10 | Incyte | 25.60 Bn | 21.07 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 36.02% |
| Mar 31, 2026 | 6.88% |
| Dec 31, 2025 | -26.29% |
| Sep 30, 2025 | -15.53% |
| Jun 30, 2025 | -27.92% |
| Mar 31, 2025 | -29.88% |
| Dec 31, 2024 | -16.77% |
| Sep 30, 2024 | 42.98% |
| Jun 30, 2024 | -68.10% |
| Mar 31, 2024 | -47.04% |
| Dec 31, 2023 | -45.27% |
| Sep 30, 2023 | 24.20% |
| Jun 30, 2023 | 40.62% |
| Mar 31, 2023 | -41.39% |
| Dec 31, 2022 | 35.83% |
| Sep 30, 2022 | 39.28% |
| Jun 30, 2022 | 36.52% |
| Mar 31, 2022 | 44.87% |
| Dec 31, 2021 | 4.79% |
| Sep 30, 2021 | 13.80% |